

Modelling circulating tumour cells for personalised survival prediction in metastatic breast cancer

Gianluca Ascolani^{1,2}, Annalisa Occhipinti^{1,2*}, Pietro Liò^{1,2}

1 University of Cambridge, Computer Laboratory, Cambridge, UK

2 These authors contributed equally to this work. * ao356@cl.cam.ac.uk

S2 Text: Full set of model equations

General case: absence of medical treatments

- cell populations in the mammary duct

$$\begin{aligned}
 \partial_t \rho(\phi, t) = & \underbrace{r_p \left(1 - \delta_{\phi,0} \frac{\tilde{\rho}_0}{C_\phi} - \sum_{\substack{0 \leq \eta \leq \Phi \\ \eta \neq \phi}} \frac{\rho(\eta, t)}{C_\eta} \right)}_{\text{symmetric cell proliferation}} \underbrace{\left(1 - \sum_{0 \leq \eta \leq \Phi} \frac{\rho(\eta, t)}{C_\eta} \right)}_{\text{cells entering the blood stream}} \frac{\rho(\phi, t)}{R_{ec}^*(\phi)^{g(\phi)}} - \underbrace{r_a R_{ec}^*(\phi)^{g(\phi)} \rho(\phi, t)}_{\text{TGF-}\beta \text{ induced apoptosis}} \\
 & + \underbrace{r_m [(1 - \delta_{\phi,0})\rho(\phi - 1, t) - (1 - \delta_{\phi,\Phi})\rho(\phi, t)]}_{\text{cell mutation}} - r_{int} (1 - \delta_{\phi,0})\rho(\phi, t) \Gamma(C_{EPC})
 \end{aligned}$$

- CTC in the circulatory system

$$\begin{aligned}
 \partial_t CTC(t) = & \underbrace{r_{int} V_{ROI} \sum_{\phi=1}^{\Phi} \rho(\phi, t) \Gamma(C_{EPC})}_{\text{intravasating CTCs}} - \underbrace{r_{imm} CTC(t) \Gamma(\overline{C_{47}} - C_{47})}_{\text{CTCs do not escape the immune system}} + \\
 & - \underbrace{r_{ext} CTC(t) \Gamma(C_{44}) \Gamma(C_{47}) \Gamma(C_{MET})}_{\text{extravasating CTCs}}
 \end{aligned}$$

- CTC_e in the bone niche

$$\partial_t CTC_e(t) = \underbrace{r_{ext} CTC(t) \Gamma(C_{44}) \Gamma(C_{47}) \Gamma(C_{MET})}_{\text{extravasating CTCs}} - \underbrace{r_{seed} CTC_e(t)}_{\text{seeding CTCs}}$$

Special case: bisphosphonate treatment

- cell populations in the mammary duct

$$\begin{aligned}
 \partial_t \rho(\phi, t) = & \underbrace{r_p \left(1 - \delta_{\phi,0} \frac{\tilde{\rho}_0}{C_\phi} - \sum_{\substack{0 \leq \eta \leq \Phi \\ \eta \neq \phi}} \frac{\rho(\eta, t)}{C_\eta} \right)}_{\text{symmetric cell proliferation}} \underbrace{\left(1 - \sum_{0 \leq \eta \leq \Phi} \frac{\rho(\eta, t)}{C_\eta} \right)}_{\text{cells entering the blood stream}} \underbrace{\frac{\rho(\phi, t)}{R_{ec}^*(\phi)^{g(\phi)}}}_{\text{TGF-}\beta \text{ induced apoptosis}} - \underbrace{r_a R_{ec}^*(\phi)^{g(\phi)} \rho(\phi, t)}_{\text{therapy effect}} \\
 + & \underbrace{r_m [(1 - \delta_{\phi,0})\rho(\phi - 1, t) - (1 - \delta_{\phi,\Phi})\rho(\phi, t)]}_{\text{cell mutation}} - \underbrace{r_{int} (1 - \delta_{\phi,0})\rho(\phi, t) \Gamma(C_{EPC})}_{\text{cells entering the blood stream}} - \underbrace{r_{BP} BP(t) \rho(\phi, t)}_{\text{therapy effect}}
 \end{aligned}$$

- *CTC* in the circulatory system

$$\begin{aligned}
 \partial_t CTC(t) = & \underbrace{r_{int} V_{ROI} \Gamma(C_{EPC}) \sum_{\phi=1}^{\Phi} \rho(\phi, t)}_{\text{intravasating CTCs}} - \underbrace{r_{imm} CTC(t) \Gamma(\overline{C_{47}} - C_{47})}_{\text{CTCs do not escape the immune system}} + \\
 & \underbrace{- r_{ext} CTC(t) \Gamma(C_{44}) \Gamma(C_{47}) \Gamma(C_{MET})}_{\text{extravasating CTCs}} - \underbrace{r_{BP} BP(t) CTC(t)}_{\text{therapy effect}}
 \end{aligned}$$

- *CTC_e* in the bone niche

$$\partial_t CTC_e(t) = \underbrace{r_{ext} CTC(t) \Gamma(C_{44}) \Gamma(C_{47}) \Gamma(C_{MET})}_{\text{extravasating CTCs}} - \underbrace{r_{seed} CTC_e(t)}_{\text{seeding CTCs}} - \underbrace{r_{BP} BP(t) CTC_e(t)}_{\text{therapy effect}}$$

- *BP* in the breast tissue, in the blood and in the bone

$$\begin{aligned}
 \partial_t BP(t) = & \underbrace{H(t - t_1) H(t_2 - t) \frac{\overline{BP}}{t_2 - t_1}}_{\text{drug administration}} - \underbrace{d_{BP} BP(t)}_{\text{drug decay}} + \\
 & \underbrace{- r_{BP} BP(t) \left[\sigma_0 \sum_{\phi=1}^{\Phi} \rho(\phi, t) + CTC(t) + CTC_e(t) \right]}_{\text{drug absorption}}
 \end{aligned}$$